Neurogene Inc.

06/04/2026 | Press release | Distributed by Public on 06/04/2026 14:41

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders
On June 3, 2026, Neurogene Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). The matters listed below were presented at the Annual Meeting. There were 11,387,407 shares of common stock present at the Annual Meeting in person or by proxy, which represented approximately 72.92% of the voting power of the shares of common stock entitled to vote at the Annual Meeting and constituted a quorum for the transaction of business. Holders of the Company's common stock were entitled to one vote for each share held as of the close of business on April 7, 2026, the record date for the Annual Meeting. A more detailed description of each of the proposals is included in the 2026 Proxy Statement. The final voting results are set forth below.
1.Election of two Class III directors, Robert Baffi and Rohan Palekar, each to serve until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified:
Nominee Shares For Shares Withheld Broker Non-Votes
Robert Baffi 9,540,734 548,736 1,297,937
Rohan Palekar 10,058,331 31,139 1,293,937
2.Approval on an advisory (non-binding) basis of the compensation of the Company's named executive officers:
Shares For Shares Against Shares Abstaining Broker Non-Votes
9,991,445 36,394 61,631 1,297,937
3.Ratification on an advisory (non-binding) basis of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026:
Shares For Shares Against Shares Abstaining
9,345,925 1,939,039 102,443
4.An advisory, non-binding vote on whether future non-binding advisory votes on the compensation paid by the Company to its named executive officers should be held every one, two or three years:
One Year Two Years Three Years Shares Abstaining Broker Non-Votes
10,006,265 3,407 16,721 63,077 1,297,937
In light of these voting results, the Company plans to hold future advisory votes on executive compensation annually until the next required vote on the frequency of such advisory votes, or until the Board of Directors of the Company otherwise determines that a different frequency is in the best interests of the Company and its stockholders.
Neurogene Inc. published this content on June 04, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 04, 2026 at 20:41 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]